by GeroSG
Turn targets found in human aging data into antibody medicines that treat more than one age-related disease, proving that aging biology can be drugged.
Preclinical. Chugai is designing antibodies against Gero's targets under the July 2025 licence.
Updated 7 Jul 2025Checked 11 Oct0 updates this week
Models follow how blood tests and diagnoses change over years in large human datasets, looking for genes tied to many diseases of age.
Gero's physics-based model splits slow, irreversible decline from reversible disease states, and ranks targets that act on the reversible part.
Chugai uses its antibody engineering to make drug candidates against those targets, then develops and sells them; Gero earns milestones and royalties.
| Spec | Aging-target antibodies (with Chugai) |
|---|---|
| Potential milestone payments | Up to ~$250MR (reported) |
| Gero equity raised (Jun 2026) | $34MR (reported) |
| Drug type | AntibodiesR (reported) |
R reported by the company
Gero
AI aging-target discovery, Chugai deal
Gero is a Singapore biotech that uses machine learning on long-term human health records to find drug targets that drive aging and several age-related diseases at once. It licenses those targets to large drug makers, most notably Chugai (Roche group). It is preclinical.
